枫蓼肠胃康胶囊联合美沙拉嗪对反复发作型溃疡性结肠炎的临床疗效及安全性

目的探讨枫蓼肠胃康胶囊联合关沙拉嗪对反复发作型溃疡性结肠炎的临床疗效。方法将2008年3月至2013年3月在原平市第一人民医院治疗的57例慢性反复发作型溃疡性结肠炎患者分为治疗组和对照组，对照组每天口服美沙拉嗪，治疗组采用枫蓼肠胃康胶囊联合美沙拉嗪。观察两组患者的临床疗效、临床症状缓解情况、肠镜、组织学检查结果以及不良反应发生情况。结果治疗组临床疗效、临床症状缓解情况、肠镜、组织学检查结果均显著优于对照组（P〈0．05）；治疗组总不良反应发生率为32．26％，明显低于对照组（53．85％）．两组比较差异有统计学意义（x2=9．506，P〈0．05）。结论枫蓼肠胃康胶囊联合美沙拉嗪治疗慢性反复发作型溃疡性结肠炎疗效优于单用美沙拉嗪，且安全性高，值得临床推广应用。

Clinical efficacy and safety of fengliaochangweikang capsule combined with mesalazine on recurrent ulcerative colitis

Objective To investigate the clinical efficacy and safety of fengliaoehangweikang capsule combined with mesalazine on patients with recurrent ulcerative colitis. Methods Fifty-seven cases of chronic recurrent ulcerative colitis from March 2008 to March 2012 in people＇ s hospital of Yuanping were divided into treatment group and control group. Patients in the control group were given oral mesalazine, patients in treatment group were given fengliaochangweikang capsule combined with mesala- zine. The clinical efficacy, clinical symptoms, endoscopy, histological examination results and adverse reactions of both groups were observed. Results Clinical symptoms and the clinical effect of treatment group, remission, endoscopy, histological examination results were significantly superior to those in the control group（P 〈 0.05）. The total incidence of adverse reaction was 32.26% in treatment group and it is significantly lower than that in control group （ 53.85% ）, the difference was statistically significant （ X2 = 9. 506, P 〈 0.05 ）. Conclusions Fengliaochangweikang capsule combined with mesalazine in treatment of Chronic recurrent type of ulcerative colitis is better titan single mesalazine, and the security is high, so it is worthy of clinical application.